Diagnosis and Treatment of Kaposi Sarcoma
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Kaposi sarcoma (KS) is the most common neoplasm of people living with HIV today. In Sub-Saharan Africa, KS is among the most common cancers in men, overall. Not only HIV-positive individuals present with KS; any immune compromised person infected with KS-associated herpesvirus (KSHV) or human herpesvirus 8 is at risk: the elderly, children in KSHV-endemic areas, and transplant recipients. KS diagnosis is based on detection of the viral protein latency-associated nuclear antigen (LANA) in the biopsy, but not all cases of KS are the same or will respond to the same therapy. Standard KS therapy has not changed in 20 years, but newer modalities are on the horizon and will be discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258
Kaufman, H. L., Russell, J., Hamid, O., Bhatia, S., Terheyden, P., D'Angelo, S. P., Shih, K. C., Lebbé, C., Linette, G. P., Milella, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30364-3 · Cited by 1,236 · cited 1×
“Immune checkpoint inhibitors have gained notoriety because of their overwhelming efficacy in a select group of immunoreactive cancers, including melanoma and polyomavirus associated Merkel cell carcinoma [133–136].”
Polizzotto, M. N., Uldrick, T. S., Wyvill, K. M., Aleman, K., Peer, C. J., Bevans, M., Sereti, I., Maldarelli, F., Whitby, D., Marshall, V., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.3812 · Cited by 138 · cited 1×
“Another group of agents, with promising clinical experiences [129–132] includes thalidomide and it’s more active derivatives pomalidomide and lenalidomide.”
Accuracy of Clinical Suspicion and Pathologic Diagnosis of Kaposi Sarcoma in East Africa
Amerson, E., Woodruff, C. M., Forrestel, A., Wenger, M., McCalmont, T., LeBoit, P., Maurer, T., Laker-Oketta, M., Muyindike, W., Bwana, M., et al. (2016) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000000862 · Cited by 56
Cited by
Overview of skin cancer types and prevalence rates across continents
Roky, A. H., Islam, M. M., Ahasan, A. M. F., Mostaq, M. S., Mahmud, M. Z., Amin, M. N., & Mahmud, M. A. (2025) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2024.08.002 · Cited by 239
Oral manifestations associated with HIV/AIDS patients
Lomelí-Martínez, S. M., González-Hernández, L. A., Ruiz-Anaya, A. D. J., Lomelí-Martínez, M. A., Martínez-Salazar, S. Y., Mercado González, A. E., Andrade-Villanueva, J. F., & Varela-Hernández, J. J. (2022) · Medicina · doi:10.3390/medicina58091214 · Cited by 107
Metadata
- Authors
- Schneider, J. W., & Dittmer, D. P.
- Venue
- American Journal of Clinical Dermatology
- Published
- 2017-03-21
- Volume
- 18
- Issue
- 4
- Pages
- 529-539
- ISSN
- 1175-0561 (ISSN-L)
- 1179-1888
- OpenAlex
- W2598076133
- Cited by
- 165
- References
- 6
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diagnosis and Treatment of Kaposi Sarcoma. https://app.cochat.ai/papers/10.1007/s40257-017-0270-4
- The paper
- Schneider, J. W., & Dittmer, D. P. (2017). Diagnosis and Treatment of Kaposi Sarcoma. American Journal of Clinical Dermatology. https://doi.org/10.1007/s40257-017-0270-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.